{"id":228,"date":"2020-04-23T09:45:00","date_gmt":"2020-04-23T16:45:00","guid":{"rendered":"https:\/\/caam.tech\/?p=228"},"modified":"2021-01-28T13:36:19","modified_gmt":"2021-01-28T21:36:19","slug":"caamtech-synthesizes-crystalline-foxtrot","status":"publish","type":"post","link":"https:\/\/caam.tech\/caamtech-synthesizes-crystalline-foxtrot\/","title":{"rendered":"CaaMTech Synthesizes Crystalline \u201cFoxtrot\u201d"},"content":{"rendered":"\n
CaaMTech researchers have synthesized and structurally characterized crystalline 5-MeO-DALT freebase (5-methoxy-diallyltryptamine, N<\/em>-allyl-N<\/em>-[2-(5-methoxy-1H-indol-3-yl)ethyl] prop-2-en-1-amine) for the very first time. The research was published in Acta Crystallographica under the title \u201c5-MeO-DALT: the freebase of N,N-diallyl-5-meth\u00adoxy\u00adtryptamine<\/a>\u201d and was conducted in collaboration with researchers at the University of Massachusetts Dartmouth. <\/p>\n\n\n\n 5-MeO-DALT, colloquially known as \u201cFoxtrot\u201d, is a psychoactive tryptamine compound. It is a structural analog of 5-MeO-DMT, which is often referred to as the \u201cGod molecule\u201d and is the most widely known psychoactive compound found in psychedelic toad secretions. Structurally, 5-MeO-DALT differs from 5-MeO-DMT by substituting both of 5-MeO-DMT\u2019s methyl groups with allyl groups. <\/p>\n\n\n\n \u201cAlthough these seem like minor changes to the structural formula, they result in substantial changes in the compound\u2019s pharmacology,\u201d commented Dr. Andrew Chadeayne, CaaMTech CEO and lead author on the paper. \u201cWe were interested in studying 5-MeO-DALT because it combines oral activity, a rapid onset time, and a short duration of action.\u201d <\/p>\n\n\n\n